CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...

Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...

A second protocol defined interim analysis is planned when approximately 50% (or 55) HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026.

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

Soligenix Inc ((SNGX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune ...